|
1
|
Higa R: Colorectal cancer: epidemiology
and primary profilaxis. Acta Gastroenterol Latinoam. 41:70–73.
2011.PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3
|
Yoon YK, Kim HP, Han SW, Oh do Y, Im SA,
Bang YJ and Kim TY: KRAS mutant lung cancer cells are
differentially responsive to MEK inhibitor due to AKT or STAT3
activation: implication for combinatorial approach. Mol Carcinog.
49:353–362. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Klatte T, Seligson DB, LaRochelle J, Shuch
B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ and
Belldegrun AS: Molecular signatures of localized clear cell renal
cell carcinoma to predict disease-free survival after nephrectomy.
Cancer Epidemiol Biomarkers Prev. 18:894–900. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee J, Kang WK, Park JO, Park SH, Park YS,
Lim HY, Kim J, Kong J, Choi MG, Sohn TS, et al: Expression of
activated signal transducer and activator of transcription 3
predicts poor clinical outcome in gastric adenocarcinoma. APMIS.
117:598–606. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yokoyama Y, Sato S, Futagami M, Fukushi Y,
Sakamoto T, Umemoto M and Saito Y: Prognostic significance of
vascular endothelial growth factor and its receptors in endometrial
carcinoma. Gynecol Oncol. 77:413–418. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bedolla R, Prihoda TJ, Kreisberg JI, Malik
SN, Krishnegowda NK, Troyer DA and Ghosh PM: Determining risk of
biochemical recurrence in prostate cancer by immunohistochemical
detection of PTEN expression and Akt activation. Clin Cancer Res.
13:3860–3867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sano T, Lin H, Chen X, Langford LA, Koul
D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK and Steck PA:
Differential expression of MMAC/PTEN in glioblastoma multiforme:
relationship to localization and prognosis. Cancer Res.
59:1820–1824. 1999.PubMed/NCBI
|
|
9
|
Lee HS, Lee HK, Kim HS, Yang HK and Kim
WH: Tumour suppressor gene expression correlates with gastric
cancer prognosis. J Pathol. 200:39–46. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang S and Yu D: PI(3)king apart PTEN’s
role in cancer. Clin Cancer Res. 16:4325–4330. 2010.PubMed/NCBI
|
|
11
|
Hameed M, Lange KH, Andersen JL,
Schjerling P, Kjaer M, Harridge SD and Goldspink G: The effect of
recombinant human growth hormone and resistance training on IGF-I
mRNA expression in the muscles of elderly men. J Physiol.
555:231–240. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Couffinhal T, Dufourcq P and Duplàa C:
Beta-catenin nuclear activation: common pathway between Wnt and
growth factor signaling in vascular smooth muscle cell
proliferation? Circ Res. 99:1287–1289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang HY, Zhang Q, Zhang X, Yu C, Huo X,
Cheng E, Wang DH, Spechler SJ and Souza RF: Cancer-related
inflammation and Barrett’s carcinogenesis: interleukin-6 and STAT3
mediate apoptotic resistance in transformed Barrett’s cells. Am J
Physiol Gastrointest Liver Physiol. 300:G454–G460. 2011.
|
|
14
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Nagayasu T and Sekine I: Expression of p-STAT3 in
human colorectal adenocarcinoma and adenoma; correlation with
clinicopathological factors. J Clin Pathol. 58:833–838. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu JR, Wang Y, Zuo LF, Li FL, Wang Y and
Liu JL: Expression and clinical significance of COX-2, p-Stat3, and
p-Stat5 in esophageal carcinoma. Ai Zheng. 26:458–462.
2007.PubMed/NCBI
|
|
16
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of
STAT3 is a marker of poor prognosis in human colorectal cancer.
Oncol Rep. 15:1445–1451. 2006.PubMed/NCBI
|
|
17
|
Senft C, Priester M, Polacin M, Schröder
K, Seifert V, Kögel D and Weissenberger J: Inhibition of the
JAK-2/STAT3 signaling pathway impedes the migratory and invasive
potential of human glioblastoma cells. J Neurooncol. 101:393–403.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kortylewski M, Kujawski M, Wang T, Wei S,
Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, et al:
Inhibiting Stat3 signaling in the hematopoietic system elicits
multicomponent antitumor immunity. Nat Med. 11:1314–1321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Joukov V, Pajusola K, Kaipainen A, Chilov
D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N and Alitalo K: A
novel vascular endothelial growth factor, VEGF-C, is a ligand for
the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
EMBO J. 15:17511996.
|
|
20
|
Tanaka T, Ishiguro H, Kuwabara Y, Kimura
M, Mitsui A, Katada T, Shiozaki M, Naganawa Y, Fujii Y and Takeyama
H: Vascular endothelial growth factor C (VEGF-C) in esophageal
cancer correlates with lymph node metastasis and poor patient
prognosis. J Exp Clin Cancer Res. 29:832010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rinderknecht M and Detmar M: Tumor
lymphangiogenesis and melanoma metastasis. J Cell Physiol.
216:347–354. 2008. View Article : Google Scholar
|
|
22
|
Han FH, Li HM, Zheng DH, He YL and Zhan
WH: The effect of the expression of vascular endothelial growth
factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in
patients with gastric carcinoma. Eur J Surg Oncol. 36:1172–1179.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang H, Kim C, Kim MJ, Schwendener RA,
Alitalo K, Heston W, Kim I, Kim WJ and Koh GY: Soluble vascular
endothelial growth factor receptor-3 suppresses lymphangiogenesis
and lymphatic metastasis in bladder cancer. Mol Cancer. 10:362011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matsuura M, Onimaru M, Yonemitsu Y, Suzuki
H, Nakano T, Ishibashi H, Shirasuna K and Sueishi K: Autocrine loop
between vascular endothelial growth factor (VEGF)-C and VEGF
receptor-3 positively regulates tumor-associated lymphangiogenesis
in oral squamoid cancer cells. Am J Pathol. 175:1709–1721. 2009.
View Article : Google Scholar
|
|
25
|
Kodama M, Kitadai Y, Tanaka M, Kuwai T,
Tanaka S, Oue N, Yasui W and Chayama K: Vascular endothelial growth
factor C stimulates progression of human gastric cancer via both
autocrine and paracrine mechanisms. Clin Cancer Res. 14:7205–7214.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bednarek W, Wertel I and Kotarski J:
Lymphangiogenesis in cancerous tumours. Ginekol Pol. 79:625–629.
2008.(In Polish).
|
|
27
|
Saharinen P, Tammela T, Karkkainen MJ and
Alitalo K: Lymphatic vasculature: development, molecular regulation
and role in tumor metastasis and inflammation. Trends Immunol.
25:387–395. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park GS, Joo YE, Kim HS, Choi SK, Rew JS,
Park CS and Kim SJ: Expression of PTEN and its correlation with
angiogenesis in gastric carcinoma. Korean J Gastroenterol.
46:196–203. 2005.PubMed/NCBI
|
|
29
|
Zhao M, Liu F, Wang JY, Zhang WY, Gao FH
and Jiang B: Effects of JAK2/STAT3 signaling pathway on
angiogenesis in non-small cell lung cancer. Zhonghua Yi Xue Za Zhi.
91:375–381. 2011.(In Chinese).
|
